Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients

Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients - Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010590

Enrollment

Registered

2013-04-24

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous T-cell lymphoma, Mycosis fungoides, Sezary&#39

Interventions

Vorinostat 400mg/day, p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histopathologically proven CTCL patients 2)Clinical stage is 1B or higher 3)Patients who don't respond to ultraviolet therapy 4)Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 5)Adequate hematologic, hepatic, renal, and cardiac function a)Absolute neutrophil count 1,500/mm3 b)Platelet >=100,000/mm3 c)Hemoglobin >=10.0g/dL d)AST and ALT <=100IU/L e)Creatinine <=1.5mg/dL 6)Patients who have given informed consent

Exclusion criteria

Exclusion criteria: 1)Patients who have treated with vorinostat 2)During treatment with systemic steroid 3)During treatment with retinoids 4)Carrier of HBV, HCV, HIV and so on 5)Patients who have severe comorbidity 6)During treatment with anti-cancer agents 7)Female who are pregnant or nursing, male hope to impregnate 8)Patients who have past history of severe allergy for vorinostat 9)Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
Feasibility	—

Secondary

Measure	Time frame
Safety Response rate Alleviation of itch	—

Countries

Japan

Contacts

Public ContactTakeru Funakoshi

Keio University, School of Medicine Depertment of Dermatology

takeruf@a8.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026